Gargiulo María de Los Ángeles, Perez Nicolás, Khoury Marina, Buhl Manuel, Suárez Lorena, Sarano Judith, Montoya Fabiana, Bazzalo Ignacio, Navarro Sandra, Pendón Gisela, Molina María Josefina, Mamani Marta, Rivero Mariano, Gómez Graciela
Servicio de Inmunología, Instituto de Investigaciones Médicas "Dr. Alfredo Lanari", UBA, Ciudad Autónoma de Buenos Aires, Argentina.
Servicio de Inmunología, Instituto de Investigaciones Médicas "Dr. Alfredo Lanari", UBA, Ciudad Autónoma de Buenos Aires, Argentina.
Reumatol Clin (Engl Ed). 2022 Jun-Jul;18(6):368-373. doi: 10.1016/j.reumae.2021.02.003. Epub 2021 Aug 6.
To describe the frequency of anti-RNA polymerase III antibody in patients with Systemic Sclerosis (SSc) of a group of healthcare centres from Argentina and to explore differences among patients with positive and negative anti-RNA polymerase III antibody.
Data from clinical records, anamnesis and physical examination were collected from 135 patients with SSc (ACR/EULAR 2013). A serum sample from each patient was obtained for the detection of anti-RNA polymerase III IgG antibodies by ELISA.
In all, 97.8% were women and the median age at diagnosis was 53 years (range 12-87), 77.7% had limited cutaneous SSc (lcSSC), 19,3% patients had diffuse cutaneous SSc (dcSSC) and 2.9% had scleroderma sine scleroderma. The 67.5% of the patients were from a Mestizos or Amerindian ethnic group. Anti-RNA polymerase III was positive in 5.9% of the patients. In 36 patients, the anticentromere (ACA) and anti-Scl70 antibodies were negative; anti-RNA polymerase III was positive in 16.7% of these 36 patients. Pitting scars and pulmonary artery hypertension were more frequent in anti-RNA polymerase III positive patients who were also older at diagnosis. No association with gastric antral vascular ectasia was found. The only patient with scleroderma renal crisis was anti-RNA polymerase III positive.
Anti-RNA polymerase III frequency found in this study was one of the lowest reported, which could be related to the predominance of the Amerindian and Mestizo ethnic group. It is possible that the detection of anti RNA polymerase III allows better classification of SSc patients, to know their prognosis and to improve their follow-up, therefore more studies are needed.
描述阿根廷一组医疗中心系统性硬化症(SSc)患者中抗RNA聚合酶III抗体的频率,并探讨抗RNA聚合酶III抗体阳性和阴性患者之间的差异。
收集135例SSc患者(ACR/EULAR 2013标准)的临床记录、病史和体格检查数据。采集每位患者的血清样本,通过酶联免疫吸附测定(ELISA)检测抗RNA聚合酶III IgG抗体。
总体而言,97.8%为女性,诊断时的中位年龄为53岁(范围12 - 87岁),77.7%为局限性皮肤型SSc(lcSSC),19.3%为弥漫性皮肤型SSc(dcSSC),2.9%为无皮肤硬化的硬皮病。67.5%的患者为混血或美洲印第安人种。5.9%的患者抗RNA聚合酶III呈阳性。在36例患者中,抗着丝点抗体(ACA)和抗Scl70抗体均为阴性;这36例患者中16.7%抗RNA聚合酶III呈阳性。抗RNA聚合酶III阳性患者中,凹陷性瘢痕和肺动脉高压更为常见,且诊断时年龄更大。未发现与胃窦血管扩张有关联。唯一一例硬皮病肾危象患者抗RNA聚合酶III呈阳性。
本研究中发现的抗RNA聚合酶III频率是报道中最低的之一,这可能与美洲印第安人和混血人种占优势有关。抗RNA聚合酶III的检测可能有助于对SSc患者进行更好的分类,了解其预后并改善随访情况,因此需要更多研究。